GlaxoSmithKline (GSK) announced a $30 billion investment plan over five years to expand drug manufacturing, research, and clinical trials in the United States, reinforcing its commitment to its largest market amid global industry shifts. This move aligns with broader trends of reshoring manufacturing capabilities influenced by government policies aimed at bolstering domestic biopharma infrastructure. Concurrently, other biopharma firms are enhancing their U.S. facilities to meet growing clinical demand and innovation priorities.